source
- Sionna’s cystic fibrosis candidate misses primary endpoint in Phase 2 trial, shares plungeSionna Therapeutics announced that its experimental cystic fibrosis drug SION-719 failed to meet the primary endpoint in a Phase 2 trial that added the drug to Vertex Pharmaceuticals' Trikafta. Th…
- Sionna Therapeutics reports early-stage cystic fibrosis trial failure, dampening challenge to VertexSionna Therapeutics said its lead cystic fibrosis drug did not meet primary endpoints in an early-stage study, marking a setback for the company. The result reduces expectations that Sionna could…